Trial · NCT04967430
TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
NCT04967430, Phase 3, Unknown, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19. Trials, record NCT04967430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04967430
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
- NCT number
- NCT04967430
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 763 participants, estimated
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Sars-CoV2, Covid19
- Interventions
- Peginterferon Lambda-1A, Placebo
- First posted
- 2021-07-19
- Last updated
- 2022-04-05
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | COVID-19 related urgent care visit, emergency room assessment, hospitalization or death by Day 28 (Primary efficacy endpoint) | At day 28 | Proportion with COVID-19-related emergency room assessment, hospitalization, or death by Day 28 |
| Primary | SARS-CoV-2 RNA negativity (Primary virological endpoint) | Day 0 to Day 28 | The time to SARS-CoV-2 RNA negativity. |
| Primary | Treatment-emergent and treatment-related serious adverse events (Primary safety endpoint) | Day 0 to Day 28 | The rate of treatment-emergent and treatment-related serious adverse events (SAEs) by Day 28. |
| Secondary | Respiratory symptom resolution (Clinical Outcome #1) | Day 0 to Day 28 | Time to resolution of respiratory symptoms. |
| Secondary | Hospitalization (Clinical outcome #2) | Day 0 to Day 28 | Hospitalization for any cause |
| Secondary | Death (Clinical outcome #3) | Day 0 to Day 28 | Death due to respiratory or cardiovascular causes |
| Secondary | All symptom resolution (Clinical outcome #4) | Day 0 to Day 28 | Time to resolution of all symptoms (return to usual state of heath). |
| Secondary | Oxygen saturation on room air (Clinical outcome #5) | Day 0 to Day 14 | Proportion of days with oxygen saturation below 93% on room air by Day 14 |
| Secondary | Seeking care from healthcare professional for COVID-19 (Clinical outcome #6) | Day 0 - Day 14 | Proportion seeking care from primary care provider/walk-in clinic or study healthcare provider for COVID-19. |
| Secondary | Hospital Admission (Clinical outcome #7) | Day 0 to Day 28 | Duration of hospital admission up to Day 28 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04967430
GET https://conductscience.org/api/trials/v1/NCT04967430/registered?page=2